Maternal serum triple analyte screening in pregnancy

Area of Science:

• Obstetrics and Gynecology
• Medical Diagnostics
• Genetics

Background:

• Prenatal screening for neural tube defects and genetic abnormalities is standard obstetric practice.
• Evolving research aims to enhance detection rates through improved maternal serum analyte combinations.
• Physicians face challenges in optimizing the sensitivity and specificity of multi-analyte screening panels.

Purpose of the Study:

• To review current prenatal screening methods and ongoing research for detecting fetal abnormalities.
• To discuss the role of specific maternal serum analytes in improving screening accuracy.
• To highlight the importance of patient counseling regarding screening risks and benefits.

Main Methods:

• Review of current standard prenatal screening analytes: alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and unconjugated estriol.
• Analysis of the diagnostic capabilities of AFP alone for neural tube defects and trisomy 21.
• Evaluation of the added value of hCG and unconjugated estriol in detecting trisomies 21 and 18.

Main Results:

• Maternal serum AFP measurement effectively detects most neural tube defects and some cases of trisomy 21.
• Incorporating hCG and unconjugated estriol into the maternal serum screen significantly improves the detection rates for trisomies 21 and 18.
• The combination of analytes offers a more comprehensive screening approach compared to AFP alone.

Conclusions:

• Current prenatal screening utilizes AFP, hCG, and unconjugated estriol to detect major fetal abnormalities.
• Combined analyte screening enhances the detection of chromosomal abnormalities like trisomy 21 and 18.
• Informed patient counseling is crucial for understanding the benefits and limitations of prenatal screening options.